Abstract
In very scarce case reports and case series, tofacitinib has been a therapeutic alternative for dermatomyositis. To corroborate the literature, we described a refractory dermatomyositis that had a good outcome with tofacitinib. Case Report: An adult female patient presented with definite dermatomyositis and with refractoriness to high doses of intravenous and oral glucocorticoids, intravenous human immunoglobulin, several immunosuppressive drugs (methotrexate, azathioprine, and leflunomide) and two previous immunobiological drugs (rituximab and abatacept). However, the patient had a good outcome with tofacitinib. Conclusions: Tofacitinib appears to be a promising alternative therapy for refractory dermatomyositis.
Highlights
Dermatomyositis (DM) is a rare systemic autoimmune myopathy associated with high functional disability [1]
In very scarce case reports and case series, tofacitinib has been a therapeutic alternative for dermatomyositis
We described a refractory dermatomyositis that had a good outcome with tofacitinib
Summary
Dermatomyositis (DM) is a rare systemic autoimmune myopathy associated with high functional disability [1]. It is standardized medicine in the treatment of ulcerative colitis, rheumatoid arthritis and psoriatic arthritis, and recently has been used as a therapeutic option for treating DM, especially for cutaneous and pulmonary conditions [2] [3] [4] [5] [6]. Patients from these studies used few immunosuppressive drugs before starting the JAK kinase inhibitor [2] [3] [4] [5] [6]. The case report includes glucocorticoid, intravenous human immunoglobulin, different immunosuppressive drugs, and two immunobiological drugs
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
